The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu
Trial record 1 of 2 for:    CTL-002
Previous Study | Return to List | Next Study

First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) (GDFATHER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04725474
Recruitment Status : Recruiting
First Posted : January 26, 2021
Last Update Posted : August 1, 2023
Information provided by (Responsible Party):
CatalYm GmbH

Brief Summary:

The Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced solid tumors.

Enrolment into the Ph 1 part is completed.

The Phase 2 parts (Part B) are cohort expansions with visugromab (CTL-002) in combination with a defined CPI at a fixed dose into seven different solid tumor indications.

Condition or disease Intervention/treatment Phase
Solid Tumor, Adult Biological: visugromab (CTL-002) Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 274 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients will be assigned to a dose level of CTL-002 (Part A) or an expansion cohort (Part B) at the time of their enrollment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
Actual Study Start Date : December 9, 2020
Estimated Primary Completion Date : October 31, 2025
Estimated Study Completion Date : October 31, 2027

Arm Intervention/treatment
Experimental: Phase 1 (Part A; dose escalation): CTL-002 Monotherapy + Checkpoint Inhibitor Combination
Up to 5 dose levels with visugromab (CTL-002) administered as IV monotherapy and in combination with a CPI
Biological: visugromab (CTL-002)
monoclonal antibody

Experimental: Phase 2 (Part B; expansion): visugromab (CTL-002) + Checkpoint Inhibitor Combination
At defined dose level(s) with visugromab (CTL-002)
Biological: visugromab (CTL-002)
monoclonal antibody

Primary Outcome Measures :
  1. Adverse Events (Parts A & B) [ Time Frame: min. 2 months ]
    Incidence of treatment emergent adverse events in monotherapy and/or combination therapy

  2. Determination of DLT and MTD (Part A) [ Time Frame: 28 days ]
    Assessment of toxicities in monotherapy and/or combination therapy per dose level

  3. Evaluation of clinical efficacy according RECIST (Part B) [ Time Frame: min. 6 weeks ]
    RECIST is measured every 6-8 weeks treatment

Secondary Outcome Measures :
  1. Cmax following the first dose of CTL-002 (Part A & B) [ Time Frame: 1 day ]
    PK parameter from serum CTL-002 levels

  2. AUC following the first dose of CTL-002 (Part A & B) [ Time Frame: 14 days ]
    PK parameter from serum CTL-002 levels

  3. Half-life of CTL-002 (Part A & B) [ Time Frame: min. 6 weeks ]
    PK parameter from serum CTL-002 levels

  4. Evaluation of treatment-emergent cytokine/chemokine concentrations (Part A & B) [ Time Frame: min. 6 weeks ]
    Measurement of concentration in peripheral blood

  5. Evaluation of clinical efficacy according RECIST (Part A) [ Time Frame: min. 6 weeks ]
    RECIST is measured every 6-8 weeks during treatment

  6. Evaluation of appetite (Part A) [ Time Frame: min. 6 weeks ]
    Assessment of appetite via quality of life questionnaire

  7. Assessment of Body-Mass-Index (BMI) (kg/m2) (Part A) [ Time Frame: min. 6 weeks ]
    Calculation of BMI in kg/m2 by combining measurement of body weight in kg and body height in cm

  8. Assessment of lumbar vertebra skeletal muscle index (L3SMI) (cm2/m2) (Part A) [ Time Frame: min. 6 weeks ]
    Combining measurement of L3 vertebra skeletal muscle mass via computed tomography (CT) in cm2 and patient height (squared) in m2

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
  • Male or female aged ≥ 18 years.
  • Relapsed/refractory patients with histologically or cytologically confirmed diagnosis of advanced-stage or recurrent cancer (Germany-specific: and have exhausted all standard of care treatments or are not eligible for such treatments)
  • Progressed on/relapsed after at least one prior anti-PD-1/PD-L1 treatment (Part A)
  • Biopsy-accessible tumor lesions and willing to undergo triple sequential tumor biopsy (Part A) and dual biopsy (Part B, only for selected cohorts).
  • At least 1 radiologically measurable lesion per RECIST V1.1/imRECIST (Part B).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Life expectancy > 3 months as assessed by the Investigator.
  • Adequate organ function (bone marrow, hepatic, renal function and coagulation).

Main Exclusion Criteria:

  • Pregnant or breastfeeding.
  • Any tumor-directed therapy within 21 days before study treatment.
  • Treatment with investigational agent within 21 days before study treatment.
  • Radiotherapy within 14 days before study treatment.
  • Pre-existing arrhythmia, uncontrolled angina pectoris, uncontrolled heart failure (NYHA) Grade IV, any myocardial infarction/coronary event, CNS-ischemic event and any thromboembolic event at any time < 6 months prior to Screening or presence of any uncontrolled heart failure NYHA Grade III or higher.
  • Left ventricular ejection fraction (LVEF) < 50% measured by echocardiogram or MUGA.
  • QTcF > 450 ms for men or > 470 ms for women.
  • Any active autoimmune requiring systemic immunosuppressive treatments. .
  • Any history of non-infectious pneumonitis < 6 months prior to Screening.
  • Any active inflammatory bowel disease such as Crohn's disease or ulcerative colitis which are generally excluded or active autoimmunthyroiditis present < 6 months prior to Screening.
  • History of CNS disease such as stroke, seizure, encephalitis, or multiple sclerosis (< 6 months prior to Screening).
  • Evidence for active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), tuberculosis (TB), or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04725474

Layout table for location contacts
Contact: Eugen Leo, MD, PhD, MBA / CMO +49 89 200066440
Contact: Petra Fettes, PhD +49 89 200066440

Layout table for location information
Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik Recruiting
Essen, Germany, 45147
Contact: Noah Trapp    +49 201 72383782      
Principal Investigator: Martin Schuler, Prof. Dr.         
Universitätsklinikum Würzburg, Comprehensive Cancer Center Recruiting
Würzburg, Germany, 97078
Contact: Franziska Goerke    +49 931 201 409 ext 57      
Contact: Julia Petzoldt- Weigel    +49 931 201 409 ext 59      
Principal Investigator: Maria-Elisabeth Goebeler, Dr.         
Sub-Investigator: Ralf Bargou, Prof. Dr.         
Sub-Investigator: Cyrus Sayehli, Dr.         
Next Oncology, Phase I Unit. IOB - Hospital Quironsalud Recruiting
Barcelona, Spain, 08023
Contact: Alonso Guzman, Dr.         
Hospital Universitari Vall d'Hebron, Institute of Oncology Recruiting
Barcelona, Spain, 08035
Contact: Elena Garralda, Dr.         
Principal Investigator: Elena Garralda Cabanas, Dr.         
ICO Hospitalet, Hospital Duran i Reynals Recruiting
Barcelona, Spain, 08908
Contact: Juan Martín Liberal, Prof. Dr.         
Hospital Universitario 12 de Octubre Recruiting
Madrid, Spain, 28041
Contact: Guillermo de Velasco, Dr.         
START Madrid, Hospital Universitario HM Sanchinarro Recruiting
Madrid, Spain, 28050
Principal Investigator: Emiliano Calvo Aller, Prof. Dr.         
Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos Recruiting
Pamplona, Spain, 31008
Principal Investigator: Ignacio Melero Bermejo, Prof. Dr.         
University Hospital Basel, Department for Medical Oncology Recruiting
Basel, Switzerland, 4031
Contact: David König, Dr.         
Kantonsspital St. Gallen, Clinic for Medical Oncology & Hematology Recruiting
Saint Gallen, Switzerland, 9007
Contact: Markus Joerger, Prof. Dr.         
University Hospital Zurich, Department of Dermatology Recruiting
Zurich, Switzerland, 9091
Contact: Reinhard Dummer, Prof. Dr.    +41 43 253 09 38      
Principal Investigator: Reinhard Dummer, Prof. Dr.         
Sponsors and Collaborators
CatalYm GmbH
Layout table for investigator information
Study Director: Eugen Leo, MD, PhD, MBA CatylYm GmbH
Layout table for additonal information
Responsible Party: CatalYm GmbH Identifier: NCT04725474    
Other Study ID Numbers: CTL-002-001
First Posted: January 26, 2021    Key Record Dates
Last Update Posted: August 1, 2023
Last Verified: July 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CatalYm GmbH: